StockData
Anika Therapeutics, Inc. logo

Anika Therapeutics, Inc. (ANIK) stock

ANIKNasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 6, 2026Score 11/30
$12.85−0.07 (-0.54%)

Close on Nov 17, 2026Market cap $171.97MP/E –Yield –

Anika Therapeutics cash

Cash and short-term investments held at the end of each period.

Anika Therapeutics's cash was $38.41M at Jun 30, 2026. For fiscal 2025 it was $81.17M, up 2.5% from the year before. Over ten years it grew -5.2% a year on average. The highest annual figure on record is $184.94M in fiscal 2019.

Annual cash

PeriodPeriod endValueChange
FY2025Dec 31, 2025$81.17M+2.5%
FY2024Dec 31, 2024$79.22M-16.7%
FY2023Dec 31, 2023$95.10M-21.4%
FY2022Dec 31, 2022$120.95M-2.6%
FY2021Dec 31, 2021$124.23M+26.4%
FY2020Dec 31, 2020$98.32M-46.8%
FY2019Dec 31, 2019$184.94M+16.3%
FY2018Dec 31, 2018$159.01M+1.1%
FY2017Dec 31, 2017$157.26M+26.0%
FY2016Dec 31, 2016$124.76M-9.9%
FY2015Dec 31, 2015$138.46M+29.5%
FY2014Dec 31, 2014$106.91M+68.8%
FY2013Dec 31, 2013$63.33M+43.7%
FY2012Dec 31, 2012$44.07M+23.2%
FY2011Dec 31, 2011$35.78M+26.9%
FY2010Dec 31, 2010$28.20M+15.5%
FY2009Dec 31, 2009$24.43M-43.4%
FY2008Dec 31, 2008$43.19M–

Quarterly cash

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$38.41M-50.2%
Q1 FY2026Mar 31, 2026$66.79M-11.4%
Q4 FY2025Dec 31, 2025$81.17M+2.5%
Q3 FY2025Sep 30, 2025$80.18M-11.6%
Q2 FY2025Jun 30, 2025$77.12M-20.2%
Q1 FY2025Mar 31, 2025$75.36M-25.2%
Q4 FY2024Dec 31, 2024$79.22M-16.7%
Q3 FY2024Sep 30, 2024$90.73M-13.9%
Q2 FY2024Jun 30, 2024$96.60M-5.1%
Q1 FY2024Mar 31, 2024$100.71M-8.8%
Q4 FY2023Dec 31, 2023$95.10M-21.4%
Q3 FY2023Sep 30, 2023$105.33M-13.6%
Q2 FY2023Jun 30, 2023$101.81M-17.6%
Q1 FY2023Mar 31, 2023$110.37M-7.8%
Q4 FY2022Dec 31, 2022$120.95M-2.6%
Q3 FY2022Sep 30, 2022$121.95M+34.0%
Q2 FY2022Jun 30, 2022$123.56M+27.1%
Q1 FY2022Mar 31, 2022$119.64M+26.5%
Q4 FY2021Dec 31, 2021$124.23M+26.4%
Q3 FY2021Sep 30, 2021$90.98M-27.1%
Q2 FY2021Jun 30, 2021$97.18M-32.7%
Q1 FY2021Mar 31, 2021$94.60M+2.5%
Q4 FY2020Dec 31, 2020$98.32M-46.8%
Q3 FY2020Sep 30, 2020$124.76M-28.0%
Q2 FY2020Jun 30, 2020$144.37M+2.1%
Q1 FY2020Mar 31, 2020$92.29M-44.7%
Q4 FY2019Dec 31, 2019$184.94M+16.3%
Q3 FY2019Sep 30, 2019$173.21M+16.2%
Q2 FY2019Jun 30, 2019$141.45M+1.5%
Q1 FY2019Mar 31, 2019$166.74M+2.3%
Q4 FY2018Dec 31, 2018$159.01M+1.1%
Q3 FY2018Sep 30, 2018$149.01M-2.4%
Q2 FY2018Jun 30, 2018$139.30M-2.5%
Q1 FY2018Mar 31, 2018$163.05M+17.6%
Q4 FY2017Dec 31, 2017$157.26M+26.0%
Q3 FY2017Sep 30, 2017$152.71M+26.9%
Q2 FY2017Jun 30, 2017$142.87M–
Q1 FY2017Mar 31, 2017$138.62M–
Q4 FY2016Dec 31, 2016$124.76M–
Q3 FY2016Sep 30, 2016$120.30M–

More Anika Therapeutics figures

See a number that looks wrong?